Literature DB >> 2702990

Phase I study of intratumoral application of recombinant human tumor necrosis factor.

M G Pfreundschuh1, H T Steinmetz, R Tüschen, V Schenk, V Diehl, M Schaadt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2702990     DOI： 10.1016/0277-5379(89)90034-5

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN： 0277-5379


× No keyword cloud information.
  13 in total

1.  The antitumour activity of the interferon inducer bropirimine is partially mediated by endogenous tumour necrosis factor alpha.

Authors:  M Scheringa; J N IJzermans; J Jeekel; R L Marquet
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

Review 2.  Tumor necrosis factor: an update on basic research and clinical applications.

Authors:  M Schleuning; R Munker
Journal:  Klin Wochenschr       Date:  1990-09-03

3.  In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon-gamma and melphalan in isolation perfusion.

Authors:  D Liénard; F J Lejeune; P Ewalenko
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

Review 4.  Delivering safer immunotherapies for cancer.

Authors:  Lauren Milling; Yuan Zhang; Darrell J Irvine
Journal:  Adv Drug Deliv Rev       Date:  2017-05-22       Impact factor: 15.470

5.  Injection of recombinant tumor necrosis factor directly into liver metastases: an experimental and clinical approach.

Authors:  J N IJzermans; M Scheringa; G P van der Schelling; R A Geerling; R L Marquet; J Jeekel
Journal:  Clin Exp Metastasis       Date:  1992-03       Impact factor: 5.150

6.  Cellular and cytokine responses of the human central nervous system to intracranial administration of tumor necrosis factor alpha for the treatment of malignant gliomas.

Authors:  M Tada; Y Sawamura; S Sakuma; K Suzuki; H Ohta; T Aida; H Abe
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

Review 7.  Improving cancer immunotherapy through nanotechnology.

Authors:  Michael S Goldberg
Journal:  Nat Rev Cancer       Date:  2019-09-06       Impact factor: 60.716

Review 8.  Employing Drug Delivery Strategies to Overcome Challenges Using TLR7/8 Agonists for Cancer Immunotherapy.

Authors:  Dhruv Varshney; Sherry Yue Qiu; Tyler P Graf; Kevin J McHugh
Journal:  AAPS J       Date:  2021-06-28       Impact factor: 4.009

9.  Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency.

Authors:  Y Tsutsumi; T Kihira; S Tsunoda; T Kanamori; S Nakagawa; T Mayumi
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

10.  Molecular design of hybrid tumour necrosis factor-alpha. II: The molecular size of polyethylene glycol-modified tumour necrosis factor-alpha affects its anti-tumour potency.

Authors:  Y Tsutsumi; S Tsunoda; H Kamada; T Kihira; S Nakagawa; Y Kaneda; T Kanamori; T Mayumi
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.